A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3

Launched by REPLIMUNE INC. · Mar 14, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to look at the long-term safety of certain treatments called RPx products in patients who have previously received at least one dose of these treatments for conditions like melanoma, advanced solid tumors, or liver cancer. The study will follow participants for five years to check for any potential delayed side effects from the RPx products. It's important to note that this is an observational study, meaning researchers will be monitoring patients without giving them new treatments during this time.

To be eligible for the study, patients must have completed or withdrawn from a related study where they received RPx treatments and must give their consent to participate. The trial is open to all adults aged 65 and older. Participants can expect regular follow-ups over the five years to ensure their health is monitored and to gather important information about their experiences after treatment. This study aims to help understand the long-term effects of these cancer treatments and ensure patient safety.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Patients are eligible for inclusion in the study only if they meet all of the following criteria:
• • 1. Patient has received at least 1 dose of an RPx product and has completed or discontinued participation in the parent study.
• • 2. Patient or patient's legal guardian has provided signed informed consent (or assent) as , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
• Exclusion Criteria:
• Patients are excluded from the study if the following criterion applies:
• • 1. Cannot comply with the requirements of the study.